Regular, low-dose, sustained-release morphine for persisting breathlessness in interstitial lung disease: a randomised, double-blind, placebo-controlled, crossover trial

Tweetable abstract

In this trial of low-dose, sustained-release morphine for breathlessness in ILD there was no clear signal of improvement; morphine was associated with more harms. Predictors of response and factors influencing perception of benefit need to be identified.https://bit.ly/45TM7Jf